

Professor Paul Watt joins Phylogica Scientific Advisory Board

PERTH, Australia, 21 November 2017: Phylogica Limited (PYC or the Company) announces that Professor Paul Watt has advised the Board that he will not stand for re-election as a director of Phylogica at the upcoming Annual General Meeting, in order to focus on his commitments as Director of Research Services and Innovation at the Telethon Kids Institute.

Professor Watt will instead join the Scientific Advisory Board as a member, while also continuing to provide services to the Company as requested by the Chief Scientific Officer, Dr Robert Hayes, under his existing Scientific Advisory Agreement.

Phylogica is very grateful to Professor Watt for the considerable services he has provided the company as both an Executive and more recently Director of the Board since the Company's formation. This appointment provides continuity of corporate knowledge and support in the development of the novel Biologics platform the Company is commercialising.

Ms Unwin said "With recent appointments at both the Board and Scientific Advisory Board levels, Phylogica is very well positioned on both the technical and scientific front as well as the commercial front to execute on our exciting strategy over the coming months."

Dr Hayes commented that "Professor Watt's appointment to the Scientific Advisory Board provides the Company with considerable expertise in the context of validating our biologics delivery platform and Professor Watt's ongoing support of Phylogica's cutting edge science is welcomed."

ENDS

For further information, please contact:

INVESTORS

Stephanie Unwin
CEO

stephanieu@phylogica.com
0411 132 287

MEDIA

Ben Walsh
WE Buchan

bwalsh@buchanwe.com.au
0411 520 01

About Phylogica

Phylogica Limited (ASX: PYC) is a biotech company focused on commercialising its intracellular drug delivery platform and panning its Phylomer libraries to identify drug cargoes for development against a wide range of disease targets. Phylogica controls access to the world's most structurally diverse source of peptides called Phylomers, which have the ability to act as effective drug delivery agents and drug cargoes, penetrating cell walls to reach previously 'undruggable' targets across a range of disease types. Phylogica's platform of proprietary cell penetration peptides is showing promise in delivering a diverse range of drug cargoes into cells. The company has had collaborations with several pharmaceutical companies including Roche, Medimmune, Pfizer, Janssen and currently with Genentech.

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Phylogica's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and Phylogica's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. Phylogica undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by Phylogica. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

Tel: +61 8 9384 3284 | Fax: +61 8 9284 3801

www.phylogica.com

Phylogica Ltd

ABN 48 098 391 961